Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression
Gespeichert in:
| Veröffentlicht in: | Multiple sclerosis 2020-09, Vol.26 (10), p.1268-1269 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1269 |
|---|---|
| container_issue | 10 |
| container_start_page | 1268 |
| container_title | Multiple sclerosis |
| container_volume | 26 |
| creator | Carandini, Tiziana Pietroboni, Anna Margherita Sacchi, Luca De Riz, Milena Alessandra Pozzato, Mattia Arighi, Andrea Fumagalli, Giorgio Giulio Martinelli Boneschi, Filippo Galimberti, Daniela Scarpini, Elio |
| description | |
| doi_str_mv | 10.1177/1352458520926459 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2442589086</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1352458520926459</sage_id><sourcerecordid>2442589086</sourcerecordid><originalsourceid>FETCH-LOGICAL-c374t-9bf242fe1c5f80f474a7c0102ca32123ab01163b62098da2af972053a31f4f083</originalsourceid><addsrcrecordid>eNp1kMtLxDAQxoMo7vq4e5KA52pebVpvy_qEhb2o15KmE400bW2Sg578042sDxA8zTDzm-9jPoSOKDmlVMozynMm8jJnpGKFyKstNKdCyoxUkmynPq2zz_0M7Xn_TAiRkue7aMaZKDhn1Ry9LzpwIb5Fpxpse-xiF-zYAfa6g2nw1uM2TrZ_xOEJ8HL9cHuR0QqPqm_BWX2OF9jZrsWx14MbO6tVgDYJGdDBDj1uwY82QJoE6H2qzsV-8HEcJ_A-EQdox6jOw-FX3Uf3V5d3y5tstb6-XS5WmeZShKxqDBPMANW5KYkRUiipCSVMK84o46ohlBa8KVIUZauYMpVkJOeKUyMMKfk-OtnojtPwEsGH-nmIU58sayYEy8uKlEWiyIbS6Xc_ganHyTo1vdaU1J-R138jTyfHX8KxcdD-HHxnnIBsA3j1CL-u_wp-AA3TiY4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2442589086</pqid></control><display><type>article</type><title>Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression</title><source>MEDLINE</source><source>SAGE Complete A-Z List</source><creator>Carandini, Tiziana ; Pietroboni, Anna Margherita ; Sacchi, Luca ; De Riz, Milena Alessandra ; Pozzato, Mattia ; Arighi, Andrea ; Fumagalli, Giorgio Giulio ; Martinelli Boneschi, Filippo ; Galimberti, Daniela ; Scarpini, Elio</creator><creatorcontrib>Carandini, Tiziana ; Pietroboni, Anna Margherita ; Sacchi, Luca ; De Riz, Milena Alessandra ; Pozzato, Mattia ; Arighi, Andrea ; Fumagalli, Giorgio Giulio ; Martinelli Boneschi, Filippo ; Galimberti, Daniela ; Scarpini, Elio</creatorcontrib><identifier>ISSN: 1352-4585</identifier><identifier>EISSN: 1477-0970</identifier><identifier>DOI: 10.1177/1352458520926459</identifier><identifier>PMID: 32463329</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adult ; Alemtuzumab - adverse effects ; Coronavirus Infections - complications ; Coronavirus Infections - immunology ; Coronavirus Infections - physiopathology ; COVID-19 ; Female ; Humans ; Immunosuppression ; Immunosuppressive Agents - adverse effects ; Immunotherapy ; Leukopenia - chemically induced ; Leukopenia - immunology ; Lymphopenia - chemically induced ; Lymphopenia - immunology ; Monoclonal antibodies ; Multiple sclerosis ; Multiple Sclerosis, Relapsing-Remitting - complications ; Multiple Sclerosis, Relapsing-Remitting - drug therapy ; Neutropenia - chemically induced ; Neutropenia - immunology ; Pandemics ; Pneumonia, Viral - complications ; Pneumonia, Viral - immunology ; Pneumonia, Viral - physiopathology ; Severity of Illness Index</subject><ispartof>Multiple sclerosis, 2020-09, Vol.26 (10), p.1268-1269</ispartof><rights>The Author(s), 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c374t-9bf242fe1c5f80f474a7c0102ca32123ab01163b62098da2af972053a31f4f083</citedby><cites>FETCH-LOGICAL-c374t-9bf242fe1c5f80f474a7c0102ca32123ab01163b62098da2af972053a31f4f083</cites><orcidid>0000-0002-0568-7580 ; 0000-0003-1538-1830 ; 0000-0002-9955-1368</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1352458520926459$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1352458520926459$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21818,27923,27924,43620,43621</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32463329$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Carandini, Tiziana</creatorcontrib><creatorcontrib>Pietroboni, Anna Margherita</creatorcontrib><creatorcontrib>Sacchi, Luca</creatorcontrib><creatorcontrib>De Riz, Milena Alessandra</creatorcontrib><creatorcontrib>Pozzato, Mattia</creatorcontrib><creatorcontrib>Arighi, Andrea</creatorcontrib><creatorcontrib>Fumagalli, Giorgio Giulio</creatorcontrib><creatorcontrib>Martinelli Boneschi, Filippo</creatorcontrib><creatorcontrib>Galimberti, Daniela</creatorcontrib><creatorcontrib>Scarpini, Elio</creatorcontrib><title>Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression</title><title>Multiple sclerosis</title><addtitle>Mult Scler</addtitle><subject>Adult</subject><subject>Alemtuzumab - adverse effects</subject><subject>Coronavirus Infections - complications</subject><subject>Coronavirus Infections - immunology</subject><subject>Coronavirus Infections - physiopathology</subject><subject>COVID-19</subject><subject>Female</subject><subject>Humans</subject><subject>Immunosuppression</subject><subject>Immunosuppressive Agents - adverse effects</subject><subject>Immunotherapy</subject><subject>Leukopenia - chemically induced</subject><subject>Leukopenia - immunology</subject><subject>Lymphopenia - chemically induced</subject><subject>Lymphopenia - immunology</subject><subject>Monoclonal antibodies</subject><subject>Multiple sclerosis</subject><subject>Multiple Sclerosis, Relapsing-Remitting - complications</subject><subject>Multiple Sclerosis, Relapsing-Remitting - drug therapy</subject><subject>Neutropenia - chemically induced</subject><subject>Neutropenia - immunology</subject><subject>Pandemics</subject><subject>Pneumonia, Viral - complications</subject><subject>Pneumonia, Viral - immunology</subject><subject>Pneumonia, Viral - physiopathology</subject><subject>Severity of Illness Index</subject><issn>1352-4585</issn><issn>1477-0970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMtLxDAQxoMo7vq4e5KA52pebVpvy_qEhb2o15KmE400bW2Sg578042sDxA8zTDzm-9jPoSOKDmlVMozynMm8jJnpGKFyKstNKdCyoxUkmynPq2zz_0M7Xn_TAiRkue7aMaZKDhn1Ry9LzpwIb5Fpxpse-xiF-zYAfa6g2nw1uM2TrZ_xOEJ8HL9cHuR0QqPqm_BWX2OF9jZrsWx14MbO6tVgDYJGdDBDj1uwY82QJoE6H2qzsV-8HEcJ_A-EQdox6jOw-FX3Uf3V5d3y5tstb6-XS5WmeZShKxqDBPMANW5KYkRUiipCSVMK84o46ohlBa8KVIUZauYMpVkJOeKUyMMKfk-OtnojtPwEsGH-nmIU58sayYEy8uKlEWiyIbS6Xc_ganHyTo1vdaU1J-R138jTyfHX8KxcdD-HHxnnIBsA3j1CL-u_wp-AA3TiY4</recordid><startdate>202009</startdate><enddate>202009</enddate><creator>Carandini, Tiziana</creator><creator>Pietroboni, Anna Margherita</creator><creator>Sacchi, Luca</creator><creator>De Riz, Milena Alessandra</creator><creator>Pozzato, Mattia</creator><creator>Arighi, Andrea</creator><creator>Fumagalli, Giorgio Giulio</creator><creator>Martinelli Boneschi, Filippo</creator><creator>Galimberti, Daniela</creator><creator>Scarpini, Elio</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><orcidid>https://orcid.org/0000-0002-0568-7580</orcidid><orcidid>https://orcid.org/0000-0003-1538-1830</orcidid><orcidid>https://orcid.org/0000-0002-9955-1368</orcidid></search><sort><creationdate>202009</creationdate><title>Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression</title><author>Carandini, Tiziana ; Pietroboni, Anna Margherita ; Sacchi, Luca ; De Riz, Milena Alessandra ; Pozzato, Mattia ; Arighi, Andrea ; Fumagalli, Giorgio Giulio ; Martinelli Boneschi, Filippo ; Galimberti, Daniela ; Scarpini, Elio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c374t-9bf242fe1c5f80f474a7c0102ca32123ab01163b62098da2af972053a31f4f083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Alemtuzumab - adverse effects</topic><topic>Coronavirus Infections - complications</topic><topic>Coronavirus Infections - immunology</topic><topic>Coronavirus Infections - physiopathology</topic><topic>COVID-19</topic><topic>Female</topic><topic>Humans</topic><topic>Immunosuppression</topic><topic>Immunosuppressive Agents - adverse effects</topic><topic>Immunotherapy</topic><topic>Leukopenia - chemically induced</topic><topic>Leukopenia - immunology</topic><topic>Lymphopenia - chemically induced</topic><topic>Lymphopenia - immunology</topic><topic>Monoclonal antibodies</topic><topic>Multiple sclerosis</topic><topic>Multiple Sclerosis, Relapsing-Remitting - complications</topic><topic>Multiple Sclerosis, Relapsing-Remitting - drug therapy</topic><topic>Neutropenia - chemically induced</topic><topic>Neutropenia - immunology</topic><topic>Pandemics</topic><topic>Pneumonia, Viral - complications</topic><topic>Pneumonia, Viral - immunology</topic><topic>Pneumonia, Viral - physiopathology</topic><topic>Severity of Illness Index</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Carandini, Tiziana</creatorcontrib><creatorcontrib>Pietroboni, Anna Margherita</creatorcontrib><creatorcontrib>Sacchi, Luca</creatorcontrib><creatorcontrib>De Riz, Milena Alessandra</creatorcontrib><creatorcontrib>Pozzato, Mattia</creatorcontrib><creatorcontrib>Arighi, Andrea</creatorcontrib><creatorcontrib>Fumagalli, Giorgio Giulio</creatorcontrib><creatorcontrib>Martinelli Boneschi, Filippo</creatorcontrib><creatorcontrib>Galimberti, Daniela</creatorcontrib><creatorcontrib>Scarpini, Elio</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Multiple sclerosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Carandini, Tiziana</au><au>Pietroboni, Anna Margherita</au><au>Sacchi, Luca</au><au>De Riz, Milena Alessandra</au><au>Pozzato, Mattia</au><au>Arighi, Andrea</au><au>Fumagalli, Giorgio Giulio</au><au>Martinelli Boneschi, Filippo</au><au>Galimberti, Daniela</au><au>Scarpini, Elio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression</atitle><jtitle>Multiple sclerosis</jtitle><addtitle>Mult Scler</addtitle><date>2020-09</date><risdate>2020</risdate><volume>26</volume><issue>10</issue><spage>1268</spage><epage>1269</epage><pages>1268-1269</pages><issn>1352-4585</issn><eissn>1477-0970</eissn><cop>London, England</cop><pub>SAGE Publications</pub><pmid>32463329</pmid><doi>10.1177/1352458520926459</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0002-0568-7580</orcidid><orcidid>https://orcid.org/0000-0003-1538-1830</orcidid><orcidid>https://orcid.org/0000-0002-9955-1368</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1352-4585 |
| ispartof | Multiple sclerosis, 2020-09, Vol.26 (10), p.1268-1269 |
| issn | 1352-4585 1477-0970 |
| language | eng |
| recordid | cdi_proquest_journals_2442589086 |
| source | MEDLINE; SAGE Complete A-Z List |
| subjects | Adult Alemtuzumab - adverse effects Coronavirus Infections - complications Coronavirus Infections - immunology Coronavirus Infections - physiopathology COVID-19 Female Humans Immunosuppression Immunosuppressive Agents - adverse effects Immunotherapy Leukopenia - chemically induced Leukopenia - immunology Lymphopenia - chemically induced Lymphopenia - immunology Monoclonal antibodies Multiple sclerosis Multiple Sclerosis, Relapsing-Remitting - complications Multiple Sclerosis, Relapsing-Remitting - drug therapy Neutropenia - chemically induced Neutropenia - immunology Pandemics Pneumonia, Viral - complications Pneumonia, Viral - immunology Pneumonia, Viral - physiopathology Severity of Illness Index |
| title | Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T07%3A33%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Alemtuzumab%20in%20multiple%20sclerosis%20during%20the%20COVID-19%20pandemic:%20A%20mild%20uncomplicated%20infection%20despite%20intense%20immunosuppression&rft.jtitle=Multiple%20sclerosis&rft.au=Carandini,%20Tiziana&rft.date=2020-09&rft.volume=26&rft.issue=10&rft.spage=1268&rft.epage=1269&rft.pages=1268-1269&rft.issn=1352-4585&rft.eissn=1477-0970&rft_id=info:doi/10.1177/1352458520926459&rft_dat=%3Cproquest_cross%3E2442589086%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2442589086&rft_id=info:pmid/32463329&rft_sage_id=10.1177_1352458520926459&rfr_iscdi=true |